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Summary
Objective: To examine the nucleoside reverse transcriptase inhibitor (NRTI) resistancemutations
in the reverse transcriptase gene of HIV-1 F1 subtype strains isolated from heavily treated
adolescents.
Methods: Three hundred and fifty reverse transcriptase (RT) genotypes with at least three NRTI
resistance mutations were included in this study; the corresponding strains were isolated from
adolescents with a complex history of antiretroviral treatment. Subtyping was done using the
publicly available algorithm REGA HIV-1&2. Resistance genotyping was performed using Big Dye
Terminator chemistry provided by the ViroSeq genotyping system. The RT gene carrying the K65R
mutation and thymidine analog mutations (TAMs) was cloned into pGEM-T vector (Promega),
followed by sequencing. In order to identify mutational clusters we calculated the binomial (phi)
correlation coefficient using SPSS 11.0 software.
Results: The analyzed sequences all belonged to the F1 subtype and were frequently carrying
TAMs associated with substitutions at position 184. TAM-2 was the pathway more frequently
encountered, and the demarcation between TAM-1 and TAM-2 was rather weak. Although the
combination of K65R mutation with TAMs has rarely been reported because of their antagonistic
effects on NRTI resistance, its presence was confirmed by clonal analysis of one strain. Four
percent of the studied genotypes presented insertions and deletions in the region 67—70 of the RT
gene and they were frequently associated with particular TAMs. Most of the NRTI resistance
mutations were found to belong to one of three distinct clusters.§ This study was presented in part at the 4th European HIV Drug Resistance Workshop, Monte Carlo, March 2006.
* Corresponding author. Tel.: +40 21 3186100x3084; fax: +40 21 3186090.
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Conclusion: Although the overall resistancemutations were not different from those described for
subtype B, the subtype F1 HIV-1 NRTI mutation patterns displayed same specificities with possible
therapeutic consequences.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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HIV-1 reverse transcriptase (RT) is the enzyme responsible for
the conversion of the RNA genome into the double-stranded
DNA molecule, which will be integrated into one of the host
chromosomes. Because it is virus-specific and has an essential
role in the replication cycle of HIV-1, this enzyme has been
the first to be targeted for antiretroviral therapy. Currently,
there are 10 drugs approved by the US Food and Drug
Administration (FDA) that are reverse transcriptase inhibi-
tors, seven of them being nucleoside reverse transcriptase
inhibitors (NRTIs) and three of them non-nucleoside reverse
transcriptase inhibitors (NNRTIs).
The combination of zidovudine (AZT) and lamivudine
(3TC) has for many years represented the main antiretroviral
(ARV) regimen. Current ARV therapy of HIV-1 infection con-
sists of associations of multiple drugs with the RTas one of the
main targets.
Distinct pathways towards resistance to NRTIs have
already been characterized.1 Thus, two different biochem-
ical mechanisms have been described to contribute to
decreased NRTI susceptibility.2,3 The first one requires the
presence of several mutations such as M184V, K65R, the
Q151M complex, and L74V that induce resistance by selec-
tively affecting the enzyme’s ability to incorporate the NRTIs
into the DNA chain.4 The other resistance mechanism is due
to a specific group of mutations collectively referred to as
thymidine analog mutations (TAMs; M41L, D67N, K70R,
L210W, T215Y/F, and K219E/Q); they promote the hydrolytic
removal of the blocking NRTI from the DNA chain by way of a
pyrophosphorolysis reaction.5 The TAMs accumulate progres-
sively into the RT gene under the selective pressure of
thymidine analogues (AZTand stavudine (d4T)); more recent
data indicate that these mutations appear in a particular
order, through two distinct pathways: TAM-1 (M41L/L210W/
T215Y) and TAM-2 (D67N/K70R/T215F/K219Q).6 There are
studies suggesting that these specific pathways may have
distinct effects on the response to treatment. For instance,
the response to tenofovir (TDF) and didanosine (ddI) is
affected by the presence of mutations of the TAM-1 pathway,
while viruses carrying TAM-2mutations are still susceptible to
those drugs.7
The HIV epidemic in Romania is characterized by the
existence of a large cohort of adolescents (16—18 years
old) who were infected in the late eighties.8 Although the
causes of this situation are not altogether clear, it is believed
that the parenteral route was the main means of transmis-
sion.9 The infective strains have been shown by sequencing to
belong almost exclusively to the F1 subtype.10 Most of these
patients have been under treatment for more than ten years:
all of them are currently on highly active antiretroviral
therapy (HAART), but many of them have experienced per-
iods (years) of either monotherapy (AZT) or bitherapy (AZT
with 3TC or zalcitabine (ddC). As many of these teenagers arebecoming sexually active, the possible transmission of strains
that have multiple drug resistance (MDR) mutations becomes
more and more a matter of concern. Knowing which are the
mutations that are prone to be transmitted and searching for
them in strains from newly infected patients (if possible, in
minority viral subpopulations) will be of crucial importance in
managing the infection. Furthermore, a better understand-
ing of the frequency, distribution, and specific associations
between mutations will be useful for better managing multi-
experienced patients.
It was therefore the purpose of this study to examine the
resistance profiles in the reverse transcriptase gene of HIV-1
F1 subtype strains isolated from Romanian heavily treated
adolescents.
Methods
Study population
Three hundred and fifty RT genotypes with at least three NRTI
resistance mutations were examined; the corresponding
strains were isolated from adolescents (17—18 years old)
with a long and frequently complex history of NRTI treat-
ment. Themutations taken into account were at positions 41,
44, 62, 65, 67, 68, 69, 70, 74, 75, 77, 115, 116, 118, 151, 184,
210, 215, 219, 333, as well as insertions and deletions at
positions 69 and 67, respectively. The HIV-1 strains were
isolated between 2003 and 2007 from patients who were
in virological failure when plasma was prelevated (viral loads
higher than 10 000 copies/ml). Most of the genotypes were
carrying four to six NRTI mutations (69.1%, 242/350), but
several sequences were carrying seven mutations and more.
We included in our analysis 34 sequences with three NRTI
mutations, 79 with four mutations, 95 sequences with five
mutations, and 68 sequences that were carrying six muta-
tions. In 47 genotypes sevenmutations were present and in 16
genotypes eight mutations were present. We also included
eight sequences with nine NRTI mutations and three geno-
types with 10 mutations.
HIV sequencing
Direct PCR sequencing (bulk sequencing) was performed with
the commercial ViroSeqTM HIV-1 genotyping system (Celera
Diagnostics), according to the manufacturer’s recommenda-
tions. Briefly, the HIV RNA genome was extracted, reverse-
transcribed, and then amplified by PCR. The resulting RT-PCR
product representing the first two thirds of the pol gene was
sequenced bidirectionally on an ABI Prism 3100-Avant genetic
analyzer (Applied Biosystems) using six different primers.
The raw analysis of the sequences wasmade using Sequencing
Analysis Software v.3.7 and then they were assembled with
ViroSeq 2.5 HIV-1 genotyping system software. The correct-
ness of each electropherogram interpretation was validated
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format. These Fasta files were then used for subtyping
purposes by comparing them with reference sequences of
all known HIV-1 subtypes. The algorithm that we used was the
publicly available REGA HIV-1&2 automated subtyping tool
version 2.0 (www.jose.med.kuleuven.be/genotypetool/
html/indexhiv.html). The resistance report generated by
ViroSeq provides a list of nucleotide mutations detected in
the RT gene (codons 1—335) known to determine resistance
to NRTIs. We used these resistance reports to describe the
NRTI resistance profile of each strain.
Cloning the reverse transcriptase gene carrying
the K65R mutation and TAMs
The first 335 codons of RT gene belonging to the 06RO1890
HIV strain were reverse-transcribed then amplified by nested
PCR and cloned into the pGEM-T vector (Promega). For this
strain, the bulk sequencing indicated that within the qua-
sispecies the K65R mutation was associated with two TAMs
(M41L and T215Y).
The RNA extraction and the RT-PCR were done using the
reagents included in the ViroSeqTM HIV-1 genotyping kit
(Celera Diagnostics). The 1.8-kb amplicon was submitted
to a second round of PCR that included the following steps:
(1) 10 minutes incubation at 95 8C (activation of Taq Gold
DNA polymerase (Applied Biosystems)), (2) 45 cycles, con-
sisting of 30 s at 95 8C, 45 s at 47 8C, and 2 min at 72 8C, and
(3) 10 minutes final extension at 72 8C. The inner primer
sequences were: 50TCAGCTTGGATCCACTTTATGTTTCCC30 as
forward primer and 50TATGTGGAATTCGCCATTCCCTGITTC30
as reverse primer. The resulting 1.065-kb amplicon was
cloned into the pGEM-T vector (Promega) according to the
manufacturer’s recommendations. The JM109 bacterial colo-
nies carrying the DNA fragment inserted into the vector were
selected on X-Gal, IPTG, and ampicillin medium. The plas-
mids were extracted using Wizard Plus SV Minipreps (Pro-
mega) and only those carrying the DNA insert were used for
the next step of the experiment. Prior to sequencing, the
target DNA was amplified by PCR using the primers described
above. The sequence of independent RT molecular clones
was determined by capillary electrophoresis on an ABI Prism
3100-Avant genetic analyzer, using the B, C, G, and H reaction
mixes included in the commercial genotyping kit. The DNA
concentration used for the sequencing reactions was of 40—
60 ng/reaction. The sequences were aligned using BioEdit
software (www.mbio.ncsu.edu/BioEdit/bioedit.html), and
an assembled full range sequence has been generated for
each clone. In order to verify the presence on the same viral
genome of K65R mutation in association with TAMs, all the
sequences obtained were aligned with HXB2 (AF033819) and
06RO1890 RTsequences and then translated into amino acids.
Statistical analysis
In order to identify patterns of NRTI resistance mutations, we
searched for correlation between 26 resistance mutations
induced by NRTI treatment by calculating the binomial (phi)
correlation coefficient, for which we used SPSS 11.0 software
(SPSS, Chicago, IL, USA). The final significance ( p) was
obtained after using the Bonferroni correction (the computedp was multiplied with the total number of comparisons). The
significance ( p) was set at 0.05.
GenBank accession numbers
The sequences reported in this paper have been submitted to
GenBank (accession numbers EU552935 to EU553271). The
nucleotide sequences obtained from the cloning experiment
encoding all the first 335 amino acids of the 06RO1890 RT
gene have GenBank accession numbers from EU032002 to
EU032015.
Results
The subtype analysis of the 350 nucleotide sequences repre-
senting the HIV-1 RT gene indicated that all of them belonged
to the F1 subtype, with a bootstrap support ranging between
82% and 100%.
TAMs were present in all the RT sequences and were
frequently associated with substitutions at position 184 as
follows: methionine was replaced with valine in 65.7% (226/
350) of sequences, with isoleucine in 6% (21/350), and both of
the variants were present in 1.4% (five genotypes). The most
frequent TAM was at position 215 (86%, 301 of studied
sequences), where threonine (T) was substituted by pheny-
lalanine (F) in 158 sequences (45.4%) or tyrosine (Y) in 143
sequences (40.9%). Other TAMs that were encountered very
frequently in the Romanian F1 sequences were D67N (70%),
K219E/Q (66.8%, of which 23.7% were K219E and 43.1% were
K219Q), and K70R (60.6%, 212/350 genotypes). The Q151M
mutation was found in 14 of the studied genotypes, often
being associated with mutations F116Y, V75I, A62V, or K65R.
Previous data have suggested that the mutation K65R,
involved in conferring variable degrees of phenotypic resis-
tance to all NRTIs, except AZTand d4T, may be prevented by
the presence of TAMs.11—13 In fact, there is some evidence
that the K65R mutation annuls the resistance to AZT caused
by TAMs, while TAMs negate resistance to TDF, abacavir
(ABC), and other NRTIs conferred by K65R.14,15 In these
conditions, the association of TAMs with K65R has rarely been
reported, especially as present on the same viral genome.
Interestingly, our data show that all the sequences carrying
the K65R mutation (6/350 genotypes) were also presenting
up to three TAMs (Table 1). To investigate the coexistence of
these two categories of mutations on the same viral genome
we performed a cloning experiment of the RT gene of one of
the six strains (06RO1890) followed by genotyping analysis.
Plasma samples for the other strains were not available.
Nineteen sequences derived from independent RT molecular
clones were selected for the genotypic analysis. In 13 of them
(68.4%), the K65R mutation was present in cis with the two
TAMs (M41L and T215Y) first detected by bulk sequencing of
the 06RO1890 strain (Table 2). This HIV-1 strain was isolated
from a multi-experienced adolescent; the ARV therapies as
well as the other mutations present in the RT gene are
summarized in Table 1.
By analyzing the genotyping data, we could also observe
nine sequences with insertions of one or two amino acids
between codons 69 and 70. Furthermore, in four genotypes
the deletion of the codon 67 was encountered. Seven of the
nine insertions were two amino acids long and the other two
Table 1 Amino acid modifications present in three RT positions involved in conferring multiple drug resistance. The resistance mutations for NNRTIs are in italic and the HIV-1
subtype F1 strain used for the cloning experiment is in bold
RT codon position Amino acid change Sequence name Other RT mutation(s) Therapy
NRTI NNRTI
69 S-SS insertion 05RO4021 62V, 215Y, 103N, 188L AZT, ddC, 3TC, d4T, ddI, ABC EFV
03RO2539 41L, 118I, 210W, 215Y
05RO6749 41L, 115F, 184V, 215F/Y AZT, 3TC, ABC, ddI EFV
05RO656 41L, 62V, 184I, 210W, 215Y, 103N d4T, ddI, 3TC, AZT, ABC EFV
S-SG insertion 05RO162 118I, 215F, 101P, 103S ddC, AZT, 3TC, d4T, ddI, ABC EFV
S-EA insertion 05RO1657 184V, 210W, 215Y, 98G AZT, ddC, d4T, ddI, ABC, 3TC EFV
S-A/GS insertion 05RO3120 41L, 67N, 74V, 118I, 184V, 215Y AZT, ddC, d4T, 3TC, ddI EFV
T-T insertion 05RO4289 70R, 219Q, 103N, 225H AZT, 3TC, d4T, ddI EFV
V-G insertion 05RO7309 41L, 44D, 67N, 210W, 215Y 3TC, AZT, ddI, ABC EFV
67 Deletion of 1 codon 05RO209 70R, 74I, 184V, 215F, 219E, 103N, 100I AZT, ddC, 3TC, d4T, ABC EFV
05RO4727 41L, 70R, 74V, 215F, 219E, 101E, 190S 3TC, ABC, d4T, ddI EFV
05RO2841 70R, 74I, 184V, 215F, 219E, 190A AZT, d4T, 3TC EFV
05RO2756 70R, 184V, 215F, 219E, 108I AZT, d4T, 3TC, ABC, ddI EFV
65 K to R substitution 03RO3466 41L,62V, 67G, 75I, 116Y, 151M, 184I, 215Y, 219E, 103N, 230L d4T, AZT, 3TC, ABC, ddI EFV
03RO521 67N, 75I/M, 77L, 219E, 103N, 181C, 190A, 238T d4T, 3TC, ABC EFV
05RO4365 41L, 62V, 67G, 75I, 116Y, 151M, 184I, 215Y, 103N, 230L AZT, d4T, 3TC, ddI, ABC EFV
03RO172 62V, 67G, 69DE, 75I, 116Y, 151M, 184I, 215Y, 103N, 230L AZT, d4T, 3TC, ddI, ABC EFV
04RO4280 41L, 62V, 67G, 75I, 116Y, 151M, 184I, 215Y, 219E, 103N, 230L d4T, AZT, 3TC, ABC, ddI EFV
06RO1890 41L, 62V, 67G, 75I, 116Y, 151M, 184I, 215Y, 103N, 230L AZT, d4T, 3TC, ddI, ABC EFV
RT, reverse transcriptase; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; AZT, zidovudine; ddC, zalcitabine; 3TC, lamivudine; d4T,
stavudine; ddI, didanosine; ABC, abacavir; EFV, efavirenz.
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Table 2 Amino acid sequences alignment of the independent RT molecular clones with HXB2 reference strain and 06RO1890 strain. The resistant variants for 41, 65 and 215 positions
are marked in bold and underlined
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Figure 1 Positive correlations between NRTI resistance muta-
tions. (a) Q151M complex and K65R; (b) TAM-1 and TAM-2 path-
ways. The pairwise binary correlation coefficient (phi) is
indicated for each line. The positive associations between muta-
tions of the two TAM pathways are distinctly marked (the phi
values are underlined). All the correlations were statistically
significant ( p < 0.01) using the Bonferroni correction.
NRTI resistance mutations in subtype F1 strains, Romania 87were only one amino acid long. Only four of the insertions fell
into the frequently reported double asparagine type;16,17 all
the rest were different and distinct among themselves. With
two exceptions, all the insertions were accompanied by
several other mutations in the RT gene (Table 1). All the
deletions were also accompanied by other resistance muta-
tions; the T215F and T219E mutations (as opposed to T215Y,
which is the most frequent substitution in strains with inser-
tions) and the substitutions at position 70 were present in all
the sequences (Table 1).
We evaluated the significance of several pairs of muta-
tions being present at two RT positions in the same genome by
using the pairwise binary (phi) correlation coefficients among
the most important 26 mutations involved in conferring
resistance to NRTIs. Twenty-four of them were point muta-
tions involving 20 positions in the RT gene, four positions
having two resistance variants, while the other two were
specific genetic rearrangements (the deletion of codon 67
and the insertion at 69 RT position). Three major clusters of
mutations have been found in our genotypes: the tightest oneconsists of mutations that confer multi resistance to NRTIs:
Q151M, F116Y, V75I, A62V, and K65R. The correlation coeffi-
cients for associations between these mutations were high,
up to 0.796 at p < 0.005 (Figure 1a). The second cluster of
mutations is formed by M41L, L210W, T215Y mutations, and
two additional ones: E44D and V118I, mutations of the TAM-1
pathway. For this cluster the values of the phi coefficient
indicated a good association that was also statistically sig-
nificant. When we examined the TAM-2 pathway, the data
were slightly different from those already reported;13,18 the
phi values for the binary D67N, K70R, K219Q, and T215F
mutation associations were smaller than those previously
described, ranging from 0.441 to 0.253. Pairwise associations
between NRTI mutations and the phi coefficient values are
presented in Figure 1.
We could also observe some associations between muta-
tions belonging to the two TAM pathways (Figure 1b). It is the
case for L210W and K219E/Q (the correlation coefficient was
0.516 with p < 0.0033) and T215Y and K219E/Q (correlation
coefficient 0.539 with p < 0.0033). Although this association
was observed, as expected, when several TAMs had already
been selected, in a number of cases (10) the only TAMs we
detected were those two that belonged to the distinct path-
ways.
Discussion
An important number of children, most of them institutio-
nalized, were infected with HIV in Romania in the late 1980s
by horizontal, presumably parenteral, transmission. The
National AIDS Committee report from September 2007
(www.cnlas.ro) indicated the existence of 10 447 AIDS cases
in Romania, of which 7411 were children at the time of the
diagnosis; the majority of them (6386) were nosocomially
infected.
Most of the survivors, now in their teens, have been
receiving monotherapy (AZT) followed by bitherapy
(AZT + 3TC) and have then been on one or more HAART
regimens. Anecdotal observations in the 1990s followed by
more thorough analyses in recent years have shown that,
rather surprisingly, the vast majority of the infecting strains
belong to the F1 subtype.8—10 pol sequencing of these strains
has revealed an important number of mutations that confer
resistance to all three classes of ARVs to which the patients
had been exposed. The RT gene presents a particular interest
due to the past treatment of the patients, one that favored
the selection of NRTI resistance mutations. It was the goal of
our study to analyze such strains with multiple RT resistance
mutations in order to detect if distinct patterns of resistance
development can be described for this rather homogeneous
pool of F1 strains.
A total of 350 genotypes, all of them harboring at least
three NRTI resistance mutations, were examined. Most of the
mutations belong to the TAM category. It is interesting to note
that although both TAM-1 and TAM-2 pathwaymutations were
encountered, the TAM-2 pathway was the better repre-
sented, in contrast with the available data obtained from
subtype B strains.18 Another interesting observation was that
the demarcation between pathways was rather weak: quite
frequently mutations belonging to the two pathways were
present even in strains that had not accumulated a large
number of mutations.
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expected finding due to the fact that of TDF, ABC, and
ddI, i.e., the molecules described to exert selective pres-
sure leading to K65R detection, TDF was not available in
Romania until 2007. One of the mutations frequently asso-
ciated with K65R was M184I, and not M184V, as observed in
subtype B strains. The existing data regard only the asso-
ciation of K65R mutation with M184V: viruses containing
this association of mutations have been shown to be more
susceptible to TDF, but more resistant to ABC and ddI
compared with viruses with only K65R.19 The effect of
the K65R and M184I association on resistance to NRTI is
unknown. Furthermore, K65R was also associated with
TAMs. This finding is in contrast with previous reports that
have suggested that not only does the association not
appear spontaneously but also when artificially introduced
it has a reciprocal effect on resistance attenuation.14 Of
course, in terms of quasispecies it can be argued that K65R
and the TAMs might not be present in cis. In order to
elucidate this, we selected a strain that had K65R asso-
ciated with M41L and T215Y and cloned the RT gene into
pGEM-T vector. The sequencing of 19 individual clones
showed that the mutations can be present in the same
genome and their association is rather frequent. It remains
to be determined if, in the context of the F1 subtype, it is
due to a bottleneck selection of a neutral association of
mutations or if the genetic modifications even confer selec-
tive advantage. In either case, the reciprocal negative
effect of K65R and TAMs seems not to be present in subtype
F strains as it was described in HIV subtype B.
The Q151M complex was present in 14 cases. The num-
ber of associated mutations was variable, ranging from
three to nine. In four of the 14 cases the K65R mutation
was present as well. Although the other mutations usually
associated with Q151M were all present in the studied
population, the 77L mutation was present in only one of
the 14 cases.
A deletion at position 67 was a resistance mutation less
frequently described. We encountered it in a relatively high
number of sequences (four). We could also identify nine
insertions between codons 69 and 70. These genetic mod-
ifications, although not very frequent, are known to be
involved in conferring MDR to nucleoside inhibitors and
appear often into an RT sequence characterized by the
presence of additional NRTI mutations.16,17 When present,
the 67 codon deletion is often associated with TAMs since it
appears mostly in heavily experienced patients. In our few
cases the position 67 deletions were associated only with
particular TAMs (T215F, K219E).
In conclusion, the dominant NRTI resistance profile found
in F1 HIV-1 subtype strains consists ofmultiple TAMs together
with substitutions at position 184. Furthermore, we could
observe other correlations between NRTI resistance muta-
tions that are partially different from those described for the
subtype B strains. We cannot exclude the possibility that the
observed patterns of correlated mutations could be the
result of pharmacological pressure imposed by the ARV regi-
mens that were administered to Romanian HIV-infected
adolescents. Further analysis that includes phenotypic data
will be necessary in order to evaluate the clinical signifi-
cance of these correlations between NRTI resistance muta-
tions.Acknowledgements
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